Blurbs

Analysts Offer Insights on Healthcare Companies: Arbutus Biopharma (ABUS), Karuna Therapeutics (KRTX) and Arcutis Biotherapeutics (ARQT)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Arbutus Biopharma (ABUSResearch Report), Karuna Therapeutics (KRTXResearch Report) and Arcutis Biotherapeutics (ARQTResearch Report) with bullish sentiments.

Arbutus Biopharma (ABUS)

In a report released today, Roy Buchanan from JMP Securities reiterated a Buy rating on Arbutus Biopharma, with a price target of $9.00. The company’s shares closed last Monday at $2.68, close to its 52-week low of $1.93.

According to TipRanks.com, Buchanan is ranked 0 out of 5 stars with an average return of -16.1% and a 28.8% success rate. Buchanan covers the Healthcare sector, focusing on stocks such as Enanta Pharmaceuticals, Hookipa Pharma, and PolyPid.

Currently, the analyst consensus on Arbutus Biopharma is a Strong Buy with an average price target of $6.33.

See Insiders’ Hot Stocks on TipRanks >>

Karuna Therapeutics (KRTX)

In a report released today, Jason Butler from JMP Securities reiterated a Buy rating on Karuna Therapeutics, with a price target of $190.00. The company’s shares closed last Monday at $117.76.

According to TipRanks.com, Butler is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -8.3% and a 37.9% success rate. Butler covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, ACADIA Pharmaceuticals, and Aquestive Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Karuna Therapeutics with a $181.17 average price target, which is a 54.9% upside from current levels. In a report issued on June 18, Jefferies also maintained a Buy rating on the stock with a $183.00 price target.

Arcutis Biotherapeutics (ARQT)

Mizuho Securities analyst Uy Ear reiterated a Buy rating on Arcutis Biotherapeutics yesterday and set a price target of $57.00. The company’s shares closed last Monday at $21.73.

According to TipRanks.com, Ear is a 1-star analyst with an average return of -4.6% and a 36.4% success rate. Ear covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, uniQure, and Avrobio.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Arcutis Biotherapeutics with a $47.75 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ABUS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
Videos

Latest News Feed